DOCSLIB.ORG

Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England V14 Changes to Version 13

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medicines Not Reimbursed Through National Prices and Directly Commissioned by Nhs England V14 Changes to Version 13 MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND V14 CHANGES TO VERSION 13 PUBLISHED APRIL 2019 Changes to v13 Lines removed SUITABLE SPECIALIST FOR CENTRE SUITABLE FOR SHARED ONLY SHARED CARE CARE PRIOR (includng WITH PRIMARY BETWEEN STOPPING MONITORING/ AUDIT APPROVAL outreach CARE (IF DRUG NAME INDICATION COMMISSIONER PBR CATEGORY TA/POLICY STARTING CRITERIA SPECIALIST COMMENT CRITERIA REQUIREMENTS PROFORMA when SUPPORTED AND REQUIRED delivered as BY LOCAL SECONDARY part of a PRESCRIBING CARE VIA provider COMMITTEE) NETWORK network) MODEL PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER ADULT TA'S (TA195, TA373, ABATACEPT NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE √ MEDICINES FOR CHILDREN TA375) POLICY) Now covered by comment 8 PAEDIATRIC INDICATIONS (IN AS PER TA455 OR ADULT TA'S (TA130 LINE WITH NHS ENGLAND (replaced by TA375), TA143 (repalced by ADALIMUMAB NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE AUDIT √ √ MEDICINES FOR CHILDREN TA383), TA146, TA187, TA199, TA329, POLICY) TA392, TA460) Now covered by comment 8 ALBUTREPENONACOG ALFA HAEMOPHILIA B PRODUCTS ON CMU Blood factor products simplified NHS ENGLAND BLOOD-RELATED PRODUCTS SSC 1652 SSC 1652 SSC 1652 √ FRAMEWORK to blood factor product VIII etc PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER IFR AS PER IFR ANAKINRA NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ MEDICINES FOR CHILDREN APPROVAL APPROVAL POLICY) Now covered by comment 8 AS PER BCSH GUIDELINES ANTIHAEMOPHILIC FACTOR/VON BCSH PRODUCTS ON CMU Blood factor products simplified FOR SPECIALISED NHS ENGLAND BLOOD-RELATED PRODUCTS BCSH GUIDELINES BCSH GUIDELINES √ WILLEBRAND FACTOR COMPLEX GUIDELINES FRAMEWORK to blood factor product VIII etc INDICATIONS PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER IFR AS PER IFR APREMILAST NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ MEDICINES FOR CHILDREN APPROVAL APPROVAL POLICY) Now covered by comment 8 INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products ARAGAM AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) AS PER IFR AS PER IFR AVORALSTAT HEREDITARY ANGIOEDEMA NHS ENGLAND ALLERGIC EMERGENCIES NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Never licensed APPROVAL APPROVAL PAEDIATRIC INDICATIONS AS PER IFR AS PER IFR BARICITINIB (WHERE ADULT TA NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL AVAILABLE) Now covered by comment 8 RESPIRATORY DISTRESS TRUST BERACTANT NHS ENGLAND PULMONARY SURFACTANTS AGREED TRUST GUIDELINES TRUST GUIDELINES √ Moving into tariff SYNDROME GUIDELINES PAEDIATRIC INDICATIONS AS PER IFR AS PER IFR BRODALIMUMAB (WHERE ADULT TA NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 APPROVAL APPROVAL AVAILABLE) CONGENITAL FACTOR XIII A- AS PER IFR AS PER IFR Blood factor products simplified CATRIDECACOG NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ SUBUNIT DEFICIENCY APPROVAL APPROVAL to blood factor product VIII etc PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER IFR AS PER IFR CERTOLIZUMAB PEGOL NHS ENGLAND CYTOKINE MODULATORS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 MEDICINES FOR CHILDREN APPROVAL APPROVAL POLICY) PAEDIATRIC INDICATIONS DRUGS AFFECTING THE IMMUNE AS PER IFR AS PER IFR COBITOLIMOD (WHERE ADULT TA NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 RESPONSE APPROVAL APPROVAL AVAILABLE) AS PER IFR AS PER IFR Changed to NRC following loss of DACLIZUMAB MULTIPLE SCLEROSIS NHS ENGLAND IMMUNOMODULATING DRUGS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL licence VIRAL HEPATITIS (B&C) & AS PER RUN RATE AS PER RUN DASABUVIR HEPATITIS C NHS ENGLAND TA 365 HEPATITIS C MDS √ √ Corrected to reflect TA status RESPIRATORY SYNCYTIAL VIRUS CARD RATE CARD PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND AS PER TA455 OR ADULT TA'S (TA103, ETANERCEPT NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE AUDIT √ √ Now covered by comment 8 MEDICINES FOR CHILDREN TA130, TA143, TA199) POLICY) PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND DRUGS AFFECTING THE IMMUNE AS PER IFR AS PER IFR ETROLIZUMAB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 MEDICINES FOR CHILDREN RESPONSE APPROVAL APPROVAL POLICY) HIGHLY HIGHLY FILGRASTIM BARTH SYNDROME NHS ENGLAND DRUGS USED IN NEUTROPENIA HIGHLY SPECIALISED CRITERIA ONLY SPECIALISED SPECIALISED √ Moving into tariff CRITERIA ONLY CRITERIA ONLY NUMBER OF PATIENTS TREATED PROPORTION GIVEN TRUST FOR SPC INDICATIONS Moving into tariff but added to FILGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA SPC TRUST GUIDELINES √ GUIDELINES WITHIN POLICY supportive drug list PRODUCT WITH LOWEST ACQUISITION COST TO BE USED PAEDIATRIC INDICATIONS (IN LINE WITH NHS ENGLAND DRUGS AFFECTING THE IMMUNE AS PER IFR AS PER IFR FILGOTINIB NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Now covered by comment 8 MEDICINES FOR CHILDREN RESPONSE APPROVAL APPROVAL POLICY) VIRAL HEPATITIS (B&C) & AS PER IFR AS PER IFR FILIBUVIR HEPATITIS C NHS ENGLAND NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Never licensed RESPIRATORY SYNCYTIAL VIRUS APPROVAL APPROVAL INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products FLEBOGAMMA AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products FLEBOGAMMADIF AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products GAMMAGARD AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products GAMMANORM AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products GAMMAPLEX AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products GAMUNEX AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) AS PER IFR AS PER IFR Blood factor products simplified GLYCOPEGYLATED FACTOR IX HAEMOPHILIA A NHS ENGLAND BLOOD-RELATED PRODUCTS NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL to blood factor product VIII etc GOLIMUMAB PAEDIATRIC INDICATIONS NHS ENGLAND CYTOKINE MODULATORS AS PER ADULTS TA'S (TA220, TA233) NICE NICE NICE AUDIT √ Now covered by comment 8 INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products HIZENTRA AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS AS PER IFR AS PER IFR Immunoglobulin products HYQVIA AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ APPROVAL APPROVAL simplified to IV or sc IMMUNOGLOBULINS PAEDIATRIC INDICATIONS (IN AS PER ADULT TA'S (TA130 (replaced LINE WITH NHS ENGLAND by TA375), TA134, TA140, TA143 INFLIXIMAB NHS ENGLAND CYTOKINE MODULATORS NICE NICE NICE AUDIT √ √ Now covered by comment 8 MEDICINES FOR CHILDREN (repalced by TA383), TA163, TA187, POLICY) TA199, TA329) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products INTRATECT AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) INTRAVENOUS/SUBCUTANEOUS CLINICAL GUIDELINES FOR NATIONAL NATIONAL Immunoglobulin products KIOVIG AS PER NATIONAL DMP NHS ENGLAND HUMAN NORMAL IMMUNOGLOBULIN USE, SECOND QUALITY DASHBOARD √ GUIDELINES GUIDELINES simplified to IV or sc IMMUNOGLOBULINS EDITION UPDATE (JULY 2011) NUMBER OF PATIENTS TREATED PROPORTION GIVEN TRUST FOR SPC INDICATIONS LENOGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA SPC TRUST GUIDELINES √ Moving into tariff GUIDELINES WITHIN POLICY PRODUCT WITH LOWEST ACQUISITION COST TO BE USED HIGHLY HIGHLY Moving into tariff but added to LENOGRASTIM BARTH SYNDROME NHS ENGLAND DRUGS USED IN NEUTROPENIA HIGHLY SPECIALISED CRITERIA ONLY SPECIALISED SPECIALISED √ supportive drug list CRITERIA ONLY CRITERIA ONLY AS PER IFR AS PER IFR LIPEGFILGRASTIM NEUTROPENIA NHS ENGLAND DRUGS USED IN NEUTROPENIA NOT ROUTINELY COMMISSIONED AS PER IFR APPROVAL √ Moving into tariff APPROVAL APPROVAL
Load more

Recommended publications
  • BCBSVT Open Formulary Prior Approval List
    BCBSVT Open Formulary Prior Approval List As of: 10/27/2020 Helpful Tip: To search for a specific drug, use the find feature (Ctrl + F) Trade Name Chemical/Biological Name Class Prior Authorization Program FUSILEV LEVOLEUCOVORIN CALCIUM ADJUNCTIVE AGENTS UNCLASSIFIED DRUG PRODUCTS KHAPZORY LEVOLEUCOVORIN ADJUNCTIVE AGENTS UNCLASSIFIED DRUG PRODUCTS LEVOLEUCOVORIN CALCIUM LEVOLEUCOVORIN CALCIUM ADJUNCTIVE AGENTS UNCLASSIFIED DRUG PRODUCTS VISTOGARD URIDINE TRIACETATE ADJUNCTIVE AGENTS UNCLASSIFIED DRUG PRODUCTS ACTHAR CORTICOTROPIN ADRENAL HORMONES HORMONES BELRAPZO BENDAMUSTINE HCL ALKYLATING AGENTS ANTINEOPLASTICS BENDAMUSTINE HCL BENDAMUSTINE HCL ALKYLATING AGENTS ANTINEOPLASTICS BENDEKA BENDAMUSTINE HCL ALKYLATING AGENTS ANTINEOPLASTICS TREANDA BENDAMUSTINE HCL ALKYLATING AGENTS ANTINEOPLASTICS DAW (DISPENSE AS WRITTEN) ALL CUSTOM BELVIQ LORCASERIN HCL ANOREXIANTS ANTI‐OBESITY DRUGS BELVIQ XR LORCASERIN HCL ANOREXIANTS ANTI‐OBESITY DRUGS CONTRAVE ER NALTREXONE HCL/BUPROPION HCL ANOREXIANTS ANTI‐OBESITY DRUGS DIETHYLPROPION HCL DIETHYLPROPION HCL ANOREXIANTS ANTI‐OBESITY DRUGS DIETHYLPROPION HCL ER DIETHYLPROPION HCL ANOREXIANTS ANTI‐OBESITY DRUGS LOMAIRA PHENTERMINE HCL ANOREXIANTS ANTI‐OBESITY DRUGS PHENDIMETRAZINE TARTRATE PHENDIMETRAZINE TARTRATE ANOREXIANTS ANTI‐OBESITY DRUGS QSYMIA PHENTERMINE/TOPIRAMATE ANOREXIANTS ANTI‐OBESITY DRUGS SAXENDA LIRAGLUTIDE ANOREXIANTS ANTI‐OBESITY DRUGS ABIRATERONE ACETATE ABIRATERONE ACETATE ANTIANDROGENS ANTINEOPLASTICS ERLEADA APALUTAMIDE ANTIANDROGENS ANTINEOPLASTICS NUBEQA DAROLUTAMIDE ANTIANDROGENS
    [Show full text]
  • DRUGS REQUIRING PRIOR AUTHORIZATION in the MEDICAL BENEFIT Page 1
    Effective Date: 08/01/2021 DRUGS REQUIRING PRIOR AUTHORIZATION IN THE MEDICAL BENEFIT Page 1 Therapeutic Category Drug Class Trade Name Generic Name HCPCS Procedure Code HCPCS Procedure Code Description Anti-infectives Antiretrovirals, HIV CABENUVA cabotegravir-rilpivirine C9077 Injection, cabotegravir and rilpivirine, 2mg/3mg Antithrombotic Agents von Willebrand Factor-Directed Antibody CABLIVI caplacizumab-yhdp C9047 Injection, caplacizumab-yhdp, 1 mg Cardiology Antilipemic EVKEEZA evinacumab-dgnb C9079 Injection, evinacumab-dgnb, 5 mg Cardiology Hemostatic Agent BERINERT c1 esterase J0597 Injection, C1 esterase inhibitor (human), Berinert, 10 units Cardiology Hemostatic Agent CINRYZE c1 esterase J0598 Injection, C1 esterase inhibitor (human), Cinryze, 10 units Cardiology Hemostatic Agent FIRAZYR icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent HAEGARDA c1 esterase J0599 Injection, C1 esterase inhibitor (human), (Haegarda), 10 units Cardiology Hemostatic Agent ICATIBANT (generic) icatibant J1744 Injection, icatibant, 1 mg Cardiology Hemostatic Agent KALBITOR ecallantide J1290 Injection, ecallantide, 1 mg Cardiology Hemostatic Agent RUCONEST c1 esterase J0596 Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units Injection, lanadelumab-flyo, 1 mg (code may be used for Medicare when drug administered under Cardiology Hemostatic Agent TAKHZYRO lanadelumab-flyo J0593 direct supervision of a physician, not for use when drug is self-administered) Cardiology Pulmonary Arterial Hypertension EPOPROSTENOL (generic)
    [Show full text]
  • AHFS Pharmacologic-Therapeutic Classification System
    AHFS Pharmacologic-Therapeutic Classification System Abacavir 48:24 - Mucolytic Agents - 382638 8:18.08.20 - HIV Nucleoside and Nucleotide Reverse Acitretin 84:92 - Skin and Mucous Membrane Agents, Abaloparatide 68:24.08 - Parathyroid Agents - 317036 Aclidinium Abatacept 12:08.08 - Antimuscarinics/Antispasmodics - 313022 92:36 - Disease-modifying Antirheumatic Drugs - Acrivastine 92:20 - Immunomodulatory Agents - 306003 4:08 - Second Generation Antihistamines - 394040 Abciximab 48:04.08 - Second Generation Antihistamines - 394040 20:12.18 - Platelet-aggregation Inhibitors - 395014 Acyclovir Abemaciclib 8:18.32 - Nucleosides and Nucleotides - 381045 10:00 - Antineoplastic Agents - 317058 84:04.06 - Antivirals - 381036 Abiraterone Adalimumab; -adaz 10:00 - Antineoplastic Agents - 311027 92:36 - Disease-modifying Antirheumatic Drugs - AbobotulinumtoxinA 56:92 - GI Drugs, Miscellaneous - 302046 92:20 - Immunomodulatory Agents - 302046 92:92 - Other Miscellaneous Therapeutic Agents - 12:20.92 - Skeletal Muscle Relaxants, Miscellaneous - Adapalene 84:92 - Skin and Mucous Membrane Agents, Acalabrutinib 10:00 - Antineoplastic Agents - 317059 Adefovir Acamprosate 8:18.32 - Nucleosides and Nucleotides - 302036 28:92 - Central Nervous System Agents, Adenosine 24:04.04.24 - Class IV Antiarrhythmics - 304010 Acarbose Adenovirus Vaccine Live Oral 68:20.02 - alpha-Glucosidase Inhibitors - 396015 80:12 - Vaccines - 315016 Acebutolol Ado-Trastuzumab 24:24 - beta-Adrenergic Blocking Agents - 387003 10:00 - Antineoplastic Agents - 313041 12:16.08.08 - Selective
    [Show full text]
  • Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria
    Oregon Medicaid Pharmaceutical Services Prior Authorization Criteria HEALTH SYSTEMS DIVISION Prior authorization (PA) criteria for fee-for-service prescriptions for Oregon Health Plan clients March 1, 2021 Contents Contents ................................................................................................................................................................ 2 Introduction........................................................................................................................................................... 7 About this guide ......................................................................................................................................... 7 How to use this guide ................................................................................................................................. 7 Administrative rules and supplemental information .................................................................................. 7 Update information............................................................................................................................................... 8 Effective March 1, 2021 ............................................................................................................................ 8 Substantive updates and new criteria ............................................................................................. 8 Clerical changes ............................................................................................................................
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • Pegvaliase-Pqpz
    Pharmacy Benefit Coverage Criteria Effective Date………….………….....................12/1/2020 Next Review Date………………………………. 12/1/2021 Coverage Policy Number ................................ P0055 Pegvaliase-pqpz Table of Contents Related Coverage Resources Medical Necessity Criteria ................................... 1 Sapropterin FDA Approved Indications ................................... 2 Recommended Dosing ........................................ 2 General Background ............................................ 3 References .......................................................... 3 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s
    [Show full text]
  • Specialty Pharmacy Program Drug List
    Specialty Pharmacy Program Drug List The Specialty Pharmacy Program covers certain drugs commonly referred to as high-cost Specialty Drugs. To receive in- network benefits/coverage for these drugs, these drugs must be dispensed through a select group of contracted specialty pharmacies or your medical provider. Please call the BCBSLA Customer Service number on the back of your member ID card for information about our contracted specialty pharmacies. All specialty drugs listed below are limited to the retail day supply listed in your benefit plan (typically a 30-day supply). As benefits may vary by group and individual plans, the inclusion of a medication on this list does not imply prescription drug coverage. Please refer to your benefit plan for a complete list of benefits, including specific exclusions, limitations and member cost-sharing amounts you are responsible for such as a deductible, copayment and coinsurance. Brand Name Generic Name Drug Classification 8-MOP methoxsalen Psoralen ACTEMRA SC tocilizumab Monoclonal Antibody/Arthritis ACTHAR corticotropin Adrenocortical Insufficiency ACTIMMUNE interferon gamma 1b Interferon ADCIRCA tadalafil Pulmonary Vasodilator ADEMPAS riociguat Pulmonary Vasodilator AFINITOR everolimus Oncology ALECENSA alectinib Oncology ALKERAN (oral) melphalan Oncology ALUNBRIG brigatinib Oncology AMPYRA ER dalfampridine Multiple Sclerosis APTIVUS tipranavir HIV/AIDS APOKYN apomorphine Parkinson's Disease ARCALYST rilonacept Interleukin Blocker/CAPS ATRIPLA efavirenz-emtricitabine-tenofovir HIV/AIDS AUBAGIO
    [Show full text]
  • Kaiser Permanente Bernard J. Tyson School of Medicine, Inc. Exclusive Provider Organization (EPO) Student Blanket Health Plan Drug Formulary
    Kaiser Permanente Bernard J. Tyson School of Medicine, Inc. Exclusive Provider Organization (EPO) Student Blanket Health Plan Drug Formulary Effective September 1, 2021 Health Plan Products: Kaiser Permanente Bernard J. Tyson School of Medicine, EPO Student Blanket Health Plan offered by Kaiser Permanente Insurance Company For the most current list of covered medications or for help understanding your KPIC insurance plan benefits, including cost sharing for drugs under the prescription drug benefit and under the medical benefit: Call 1-800-533-1833, TTY 711, Monday through Friday, 7 a.m. to 9 p.m. ET Visit kaiserpermanente.org to: • Find a participating retail pharmacy by ZIP code. • Look up possible lower-cost medication alternatives. • Compare medication pricing and options. • Find an electronic copy of the formulary here. • Get plan coverage information. For cost sharing information for the outpatient prescription drug benefits in your specific plan, please visit kp.org/kpic-websiteTBD The formulary is subject to change and all previous versions of the formulary are no longer in effect. Kaiser Permanente Last updated: September 1, 2021 Table of Contents Informational Section...........................................................................................................................................3 ANTIHISTAMINE DRUGS - Drugs for Allergy.....................................................................................................9 ANTI-INFECTIVE AGENTS - Drugs for Infections...........................................................................................
    [Show full text]
  • Recent Advances in Oligonucleotide Therapeutics in Oncology
    International Journal of Molecular Sciences Review Recent Advances in Oligonucleotide Therapeutics in Oncology Haoyu Xiong 1, Rakesh N. Veedu 2,3 and Sarah D. Diermeier 1,* 1 Department of Biochemistry, University of Otago, Dunedin 9016, New Zealand; [email protected] 2 Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Perth 6150, Australia; [email protected] 3 Perron Institute for Neurological and Translational Science, Perth 6009, Australia * Correspondence: [email protected] Abstract: Cancer is one of the leading causes of death worldwide. Conventional therapies, including surgery, radiation, and chemotherapy have achieved increased survival rates for many types of cancer over the past decades. However, cancer recurrence and/or metastasis to distant organs remain major challenges, resulting in a large, unmet clinical need. Oligonucleotide therapeutics, which include antisense oligonucleotides, small interfering RNAs, and aptamers, show promising clinical outcomes for disease indications such as Duchenne muscular dystrophy, familial amyloid neuropathies, and macular degeneration. While no approved oligonucleotide drug currently exists for any type of cancer, results obtained in preclinical studies and clinical trials are encouraging. Here, we provide an overview of recent developments in the field of oligonucleotide therapeutics in oncology, review current clinical trials, and discuss associated challenges. Keywords: antisense oligonucleotides; siRNA; aptamers; DNAzymes; cancers Citation: Xiong, H.; Veedu, R.N.; 1. Introduction Diermeier, S.D. Recent Advances in Oligonucleotide Therapeutics in According to the Global Cancer Statistics 2018, there were more than 18 million new Oncology. Int. J. Mol. Sci. 2021, 22, cancer cases and 9.6 million deaths caused by cancer in 2018 [1].
    [Show full text]
  • PALYNZIQ (Pegvaliase-Pqpz) Injection, for Subcutaneous Use Blood Phenylalanine Monitoring and Diet (2.2) Initial U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION 600 micromol/L after 16 weeks of continuous treatment with the These highlights do not include all the information needed to use maximum dosage of 40 mg once daily. PALYNZIQ safely and effectively. See full prescribing information for Reduce the dosage and/or modify dietary protein and phenylalanine PALYNZIQ. intake, as needed, to maintain blood phenylalanine concentrations within a clinically acceptable range and above 30 micromol/L. PALYNZIQ (pegvaliase-pqpz) injection, for subcutaneous use Blood Phenylalanine Monitoring and Diet (2.2) Initial U.S. Approval: 2018 Obtain blood phenylalanine concentrations every 4 weeks until a maintenance dosage is established. WARNING: RISK OF ANAPHYLAXIS After a maintenance dosage is established, periodically monitor blood See full prescribing information for complete boxed warning. phenylalanine concentrations. Anaphylaxis has been reported after administration of Palynziq Counsel patients to monitor dietary protein and phenylalanine intake, and may occur at any time during treatment. (5.1) and adjust as directed by their healthcare provider. Administer the initial dose of Palynziq under the supervision of a Premedication (2.3, 5.1, 5.3) healthcare provider equipped to manage anaphylaxis, and closely Consider premedication for hypersensitivity reactions. observe patients for at least 60 minutes following injection. Prior Administration Instructions (2.4) to self-injection, confirm patient competency with Rotate injection sites. If more than one injection is needed for a single self-administration, and patient’s and observer’s (if applicable) dose, the injection sites should be at least 2 inches away from each other. ability to recognize signs and symptoms of anaphylaxis and to administer auto-injectable epinephrine, if needed.
    [Show full text]
  • 2020 Medicaid Preapproval Criteria
    2020 Medicaid Preapproval Criteria ABILIFY MAINTENA ................................................................................................................................................................ 10 ACTHAR HP ............................................................................................................................................................................ 11 ACTIMMUNE ......................................................................................................................................................................... 13 ADCIRCA ................................................................................................................................................................................ 14 ADEMPAS .............................................................................................................................................................................. 15 ADENOSINE DEAMINASE (ADA) REPLACEMENT ................................................................................................................... 17 AFINITOR ............................................................................................................................................................................... 18 AFINITOR DISPERZ ................................................................................................................................................................. 19 ALDURAZYME .......................................................................................................................................................................
    [Show full text]
  • Self-Administered Specialty Drug List
    Self‐Administered Drug List BRAND NAME GENERIC DRUG NME ABIRATERONE ACETATE ABIRATERONE ACETATE ACTEMRA TOCILIZUMAB ACTEMRA ACTPEN TOCILIZUMAB ACTHAR CORTICOTROPIN ACTIMMUNE INTERFERON GAMMA‐1B,RECOMB ADCIRCA TADALAFIL ADEMPAS RIOCIGUAT AFINITOR EVEROLIMUS AFINITOR DISPERZ EVEROLIMUS ALECENSA ALECTINIB HCL ALUNBRIG BRIGATINIB ALYQ TADALAFIL AMBRISENTAN AMBRISENTAN AMPYRA DALFAMPRIDINE APOKYN APOMORPHINE HCL ARANESP DARBEPOETIN ALFA IN POLYSORBAT ARCALYST RILONACEPT ARIKAYCE AMIKACIN LIPOSOMAL/NEB.ACCESSR ARIXTRA FONDAPARINUX SODIUM AUBAGIO TERIFLUNOMIDE AUSTEDO DEUTETRABENAZINE AVEED TESTOSTERONE UNDECANOATE AVONEX INTERFERON BETA‐1A AVONEX INTERFERON BETA‐1A/ALBUMIN AVONEX PEN INTERFERON BETA‐1A AYVAKIT AVAPRITINIB BAFIERTAM MONOMETHYL FUMARATE BALVERSA ERDAFITINIB BENLYSTA BELIMUMAB BETASERON INTERFERON BETA‐1B BETHKIS TOBRAMYCIN BOSENTAN BOSENTAN BOSULIF BOSUTINIB BRAFTOVI ENCORAFENIB BRONCHITOL MANNITOL BRUKINSA ZANUBRUTINIB BYNFEZIA OCTREOTIDE ACETATE CABENUVA CABOTEGRAVIR/RILPIVIRINE CABLIVI CAPLACIZUMAB‐YHDP CABOMETYX CABOZANTINIB S‐MALATE CALQUENCE ACALABRUTINIB CAPECITABINE CAPECITABINE CAPRELSA VANDETANIB CARBAGLU CARGLUMIC ACID CAYSTON AZTREONAM LYSINE CERDELGA ELIGLUSTAT TARTRATE CETROTIDE CETRORELIX ACETATE CHENODAL CHENODIOL CHOLBAM CHOLIC ACID CHORIONIC GONADOTROPIN CHORIONIC GONADOTROPIN, HUMAN CIMZIA CERTOLIZUMAB PEGOL COPAXONE GLATIRAMER ACETATE COPIKTRA DUVELISIB COSENTYX (2 SYRINGES) SECUKINUMAB COSENTYX PEN SECUKINUMAB COSENTYX PEN (2 PENS) SECUKINUMAB COSENTYX SYRINGE SECUKINUMAB COTELLIC COBIMETINIB FUMARATE CYSTADANE
    [Show full text]